MX2015012716A - Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. - Google Patents

Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.

Info

Publication number
MX2015012716A
MX2015012716A MX2015012716A MX2015012716A MX2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A
Authority
MX
Mexico
Prior art keywords
dipyridamole
compositions
eye disorders
treating eye
topically
Prior art date
Application number
MX2015012716A
Other languages
English (en)
Spanish (es)
Inventor
Moshe Rogosnitzky
Original Assignee
Remedeye Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedeye Inc filed Critical Remedeye Inc
Publication of MX2015012716A publication Critical patent/MX2015012716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2015012716A 2013-03-12 2014-03-11 Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. MX2015012716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compounds for use in ocular disorders using dipyridamole
PCT/IB2014/059645 WO2014141079A1 (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Publications (1)

Publication Number Publication Date
MX2015012716A true MX2015012716A (es) 2016-07-06

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012716A MX2015012716A (es) 2013-03-12 2014-03-11 Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.

Country Status (14)

Country Link
EP (1) EP2968328A4 (ko)
JP (1) JP6820658B2 (ko)
KR (2) KR20210010638A (ko)
CN (1) CN105188702B (ko)
AU (1) AU2014229371B2 (ko)
BR (1) BR112015022084A2 (ko)
CA (1) CA2905594A1 (ko)
CL (1) CL2015002627A1 (ko)
EA (1) EA035966B1 (ko)
IL (1) IL225179A (ko)
MX (1) MX2015012716A (ko)
MY (1) MY182591A (ko)
SG (2) SG11201507092QA (ko)
WO (1) WO2014141079A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016212527B2 (en) * 2015-01-28 2019-03-07 Realinn Life Science Limited Compounds for enhancing PPARgamma expression and nuclear translocation and therapeutic use thereof
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001806A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
WO2021001805A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations and their methods of preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CN101355876B (zh) * 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
EP2363126A1 (en) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation

Also Published As

Publication number Publication date
JP6820658B2 (ja) 2021-01-27
IL225179A (en) 2017-01-31
AU2014229371B2 (en) 2018-05-10
EP2968328A1 (en) 2016-01-20
EA201591653A1 (ru) 2017-05-31
BR112015022084A2 (pt) 2017-07-18
KR20210010638A (ko) 2021-01-27
SG10201706937UA (en) 2017-09-28
EP2968328A4 (en) 2016-11-23
AU2014229371A1 (en) 2015-10-29
CN105188702A (zh) 2015-12-23
CA2905594A1 (en) 2014-09-18
MY182591A (en) 2021-01-26
KR20150126021A (ko) 2015-11-10
SG11201507092QA (en) 2015-10-29
JP2016514123A (ja) 2016-05-19
WO2014141079A1 (en) 2014-09-18
CL2015002627A1 (es) 2016-03-11
EA035966B1 (ru) 2020-09-07
CN105188702B (zh) 2019-03-26
IL225179A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX364486B (es) Derivados de piridazinona-amidas.
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
EA201591628A1 (ru) Дейтерированный палбоциклиб
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UA115357C2 (uk) Похідні піридин-4-ілу
MX2016016404A (es) Metodos para el tratamiento del prurito.
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
EP2910247A4 (en) COMPOSITIONS FOR PREVENTING OR TREATING ALLERGIC SKIN DISORDERS CONTAINING GPCR19 AGENTS AS ACTIVE INGREDIENTS
EA201491878A1 (ru) Замещенные ксантиновые производные
MX366805B (es) Uso de sulfato de zinc coceth como un agente antibacteriano en contra de propionibacterium acnes.
MX2016014261A (es) Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis.
NZ764041A (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis